KEY DETAILS
A new obesity drug from Boehringer and Zealand Pharma helped diabetes patients lose up to 13.1% of their weight, a result seen as disappointing, as 10 more drugmakers join the 340B pilot program.
Fresh trial data on Eli Lilly's obesity drug is adding competitive pressure on rival Novo Nordisk.
Federal prosecutors have charged two people in a scheme to sell counterfeit Ozempic.
A study found that trevogrumab cut semaglutide-induced lean mass loss by half for patients on GLP-1 therapy.
The Phase 2 COURAGE trial confirmed that trevogrumab can prevent lean mass and muscle loss during GLP-1 receptor agonist weight loss.
Boehringer and Zealand Pharma's obesity drug helped diabetes patients lose up to 13.1% of their weight in new trial results, a figure that lands below what rivals have posted. The result arrived the same day ten more drugmakers joined the 340B pilot program, while fresh data from Eli Lilly added pressure on Novo Nordisk. Federal prosecutors also charged two people over counterfeit Ozempic, and a new study pointed to a possible fix for one of GLP-1 therapy's persistent side effects: muscle loss.
The 13.1% figure for Boehringer and Zealand Pharma's drug came from patients with diabetes, and it sits below what the leading obesity treatments have already shown in similar trials. That gap matters because the obesity drug market has grown crowded, and a new treatment needs a clear edge to stand out once it reaches pharmacies. The same day, ten additional drugmakers signed onto the 340B pilot program, an initiative meant to widen access to these medications for lower income patients. Together the two developments suggest a market that is expanding in reach even as some of its newest entrants struggle to clear the bar set by current leaders.
That bar is only getting higher. Fresh trial data on Eli Lilly's obesity drug landed today and added to the competitive pressure Novo Nordisk is already facing, as the two companies continue to trade places at the top of the obesity drug market. For Novo, the timing is not ideal, coming as attention has already turned toward which company can deliver the strongest results with the fewest tradeoffs. Patients and doctors watching this competition stand to benefit if it pushes companies toward drugs with better results and fewer downsides.
Competition among legitimate drugmakers is one story. But as demand for these medications has grown, so has the market for fake versions, and today federal prosecutors charged two people in a scheme to sell counterfeit Ozempic. The charges are a reminder that patients should get these medications through verified pharmacies and legitimate prescriptions, since the ingredients and dosing in counterfeit products are not guaranteed. Anyone who suspects they have received a counterfeit product should raise it with their pharmacist or doctor right away.
On the research side, a new study offered more encouraging news for patients on legitimate GLP-1 therapy. Researchers found that trevogrumab cut the lean mass loss associated with semaglutide roughly in half, addressing a concern many patients raise about these drugs: that some of the weight lost comes from muscle rather than fat. That distinction matters because lean mass supports strength and metabolic health, and losing too much of it can offset some of the benefits of weight loss. The finding suggests that pairing GLP-1 therapy with a drug like trevogrumab could change how doctors approach long term treatment.
That early finding was reinforced by the Phase 2 COURAGE trial, which confirmed that trevogrumab can prevent lean mass and muscle loss during weight loss driven by GLP-1 receptor agonists. The trial results give doctors a clearer picture of how trevogrumab performs alongside these drugs, rather than relying on a single study. If the results hold up in larger trials, they could support a treatment approach that preserves muscle while patients still lose fat. That would address one of the more common tradeoffs patients and doctors have raised about GLP-1 therapy since it became widely used.
Readers weighing options in obesity treatment may want to keep an eye on the trevogrumab research, since muscle preservation has become one of the more important questions in long term GLP-1 use. The counterfeit Ozempic charges are also a good prompt to confirm that any prescription comes from a licensed pharmacy rather than an unverified seller. Before acting on any of today's developments, talk with your doctor about whether they change anything about your own treatment plan.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.